Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD30 biAb-AATC in Relapsed/Refractory CD30+ Hematopoietic Malignancies
NCT05544968Phase 1Recruiting
- Sponsor
- Medical College of Wisconsin
- Start
- Mar 2026
- Primary completion
- Jan 2028
- Modality
- Cell Therapies, T-cell Engagers
- Countries
- 1
01
Overview
Phase 1, open-label trial of CD30 biAb-AATC in Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), acute myeloid leukemia (AML) and 1 more (5 arms), sponsored by Medical College of Wisconsin. Primary endpoint: Maximum Tolerated Dose at 2 years. Started Mar 2026; status: recruiting.
02
Drugs
CD30 biAb-AATC
03
Conditions
Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT05544968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05544968.